This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human Semaphorin 4A / SEMA4A Protein, His Tag
catalog :
SEA-H5224
quantity :
100 ug, 1 mg
price :
260 USD, 1600 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
SEA-H5224
product name :
Human Semaphorin 4A / SEMA4A Protein, His Tag
quantity :
100 ug, 1 mg
price :
260 USD, 1600 USD
quantity & price :
$260/100ug,$1600/1mg (500ug × 2)
target :
Semaphorin 4A
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human Semaphorin 4A, His Tag (SEA-H5224) is expressed from human 293 cells (HEK293). It contains AA Gly 33 - His 683 (Accession # AAH20974).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human Semaphorin 4A, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Semaphorin-4A (SEMA4A) is also known as Semaphorin-B (SEMAB), which belongs to the semaphorin family. SEMA4A contains one Ig-like C2-type (immunoglobulin-like) domain, one PSI domain and one sema domain. SEMA4A is cell surface receptor for PLXNB1, PLXNB2, PLXNB3 and PLXND1 that plays an important role in cell-cell signaling. SEMA4A plays a role in priming antigen-specific T-cells, promotes differentiation of Th1 T-helper cells, and thereby contributes to adaptive immunity. SEMA4A also promotes phosphorylation of TIMD2 and inhibits angiogenesis. SEMA4A promotes axon growth cone collapse and inhibits axonal extension by providing local signals to specify territories inaccessible for growing axons.
References :
(1) Abid A., et al., 2006, J. Med. Genet. 43:378-381.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments